Transcutaneous Vagus Nerve Stimulation for Gait and Motor Function in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the effects of transcutaneous vagus nerve stimulation (tVNS) on gait, motor function, and freezing of gait (FOG) in patients with Parkinson’s disease…Positive Relationship Between Improvement in Sleep and Quality of Life During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion
Objective: To investigate the relationship between improvements in sleep disturbances and quality of life (QoL) in adults with advanced Parkinson’s disease (aPD) treated with a…Botulinium toxin in treatment of Parkinsonism
Objective: This review discusses the use of BT in various motor and non-motor symptoms of Parkinsonism. This review discusses the use of BT in various…Effect of Reaction Oriented Training on Postural Stability and Reaction Time in Parkinsons’s Disease
Objective: This study aimed to examine the effect of reaction-oriented training (ROT), a novel rehabilitation approach developed for people with Parkinson's disease (pwPD), on postural…Continued Evaluation of Bemdaneprocel Following a Phase 1 Study for Parkinson’s Disease: Outcomes Through 3 Years
Objective: To report the safety and clinical outcomes of bemdaneprocel in participants with Parkinson’s disease (PD) through 3 years post transplantation. Background: Bemdaneprocel is an…Safety, Tolerability, and Preliminary Efficacy of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease: A Multi-center, Open Label, Phase 1 Study
Objective: This Phase 1 study aims to evaluate the safety, tolerability, preliminary efficacy, and optimal dose of NouvNeu001 for treating mid to late-stage Parkinson’s disease…Safinamide as an Adjunct Therapy for Motor Symptoms and ON-Time Extension in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy of safinamide as an adjunct therapy in improving motor symptoms and extending ON-time in patients with Parkinson’s disease (PD). Background:…CSM-101 is a Small Molecule Agonist of TRPML1 for Parkinson’s-Related Disorders
Objective: (i) To develop a brain-penetrant small molecule agonist for the lysosomal TRPML1 channel and, (ii) Perform preclinical studies supporting development in Parkinson’s-related disorders. Background:…Coping with Parkinson’s Disease through the Lens of Personality Systems Interactions (PSI) Theory: Two Case Studies
Objective: This study examines how concepts from motivation and personality research contribute to understanding coping strategies in individuals with Parkinson’s disease (PD). Background: Effective treatment…Ferritin-related Brain Iron Deposition in Parkinson’s Disease Involves α-Synuclein Pathology
Objective: To investigate plasma neuron-derived ferritin-containing extracellular vesicles (NDFEVs) differences between Parkinson’s disease (PD) patients and controls, assess their association with brain iron deposition, and explore the…
- « Previous Page
- 1
- …
- 331
- 332
- 333
- 334
- 335
- …
- 1942
- Next Page »